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Background: Gluteal tendinopathy is a common cause of lateral hip pain, and existing conservative treatment modalities dem-
onstrate high symptom recurrence rates. Autologous tenocyte injection (ATI) is a promising cell therapy that may be useful for the
treatment of gluteal tendinopathy.
Purpose: To investigate the safety and effectiveness of ATI, specifically in patients with chronic recalcitrant gluteal tendinopathy.
Study Design: Case series; Level of evidence, 4.
Methods: Twelve female patients with a clinical and radiological diagnosis of gluteal tendinopathy were recruited. Patients
demonstrated a mean duration of symptoms of 33 months (range, 6-144 months), had undergone a mean 3.2 prior corticosteroid
injections (range, 2-5), and had failed to respond to existing conservative treatments including physiotherapy and injections. In an
initial procedure, tendon cells were harvested from a needle biopsy of the patella tendon and propagated in a certified Good
Manufacturing Practice (GMP) laboratory. In a secondary procedure, a single injection of 2 mL autologous tenocytes (2-5  106
cells/mL) suspended in patient serum was injected into the site of the pathological gluteal tendons under ultrasound guidance.
Patients were assessed pre- and postinjection (3, 6, 12, and 24 months) using the Oxford Hip Score (OHS), a visual analog pain
scale (VAS), the Short Form–36 (SF-36), and a satisfaction scale. Magnetic resonance imaging (MRI) was undertaken at 8.7 months
(range, 6-12 months) postinjection.
Results: Molecular characterization of autologous tendon cells showed a profile of growth factor production in all cases, including
platelet-derived growth factor a, fibroblast growth factor b, and transforming growth factor b. The OHS (mean, 24.0 preinjection to
38.9 at 12 months [14.9-point improvement]; 95% CI, 10.6-19.2; P < .001), VAS (mean, 7.2 preinjection to 3.1 at 12 months
[4.1-point improvement]; 95% CI, 2.6-5.6; P < .001), and SF-36 (mean, 28.1 preinjection to 43.3 at 12 months [15.2-point
improvement]; 95% CI, 9.8-20.5; P < .001) significantly improved to 12 months postinjection, sustained to 24 months. Eight
patients were satisfied with their outcomes. Significant MRI-based improvement could not be demonstrated in the majority of cases.
Conclusion: ATI for gluteal tendinopathy is safe, with improved and sustained clinical outcomes to 24 months.
Keywords: autologous tenocyte implantation; gluteal tendinopathy; greater trochanteric pain syndrome; cellular therapy; clinical
outcomes
Greater trochanteric pain syndrome (GTPS) is a term used
to define the clinical condition of greater and peritrochan-
teric hip pain and tenderness,12-14,17,23,28 affecting 10% to
25% of the general population.18,23,28 While previously
reported as trochanteric bursitis, gluteus medius and/or
minimus tendinopathy is now accepted as the most preva-
lent pathology in those with pain and tenderness over the
greater trochanter.11 Histological changes in tendinopathy
include decreased and disorganized collagen production,
deposition of adipose tissue, vascular hyperplasia charac-
terized by an absence of polymorphonucleocytes, variation
in cell populations, and disruption of the extracellular
matrix.29 Apoptosis and autophagic tendon cell death
occurs in more severe cases,3 and increased cell death rates
in chronic lateral epicondylitis and rotator cuff tendinopa-
thy indicate that the healing process is suppressed by a
lack of cellular components.24 The depleted cell population
and reduced collagen synthesis accelerate collagen
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deterioration, compromising the ability of the tendon to
maintain structural integrity.29
Conservative treatments for gluteal tendinopathy may
include rest, anti-inflammatory medication, ice and/or
heat, physical therapy, shock wave therapy, ultrasound,
and local corticosteroid injections.8,15,22,28 However, a high
symptom recurrence rate at 1 year has been demonstrated
for all conservative treatment modalities in primary care,18
and patients frequently undergo multiple courses of non-
operative treatment with only temporary pain relief.19
Autologous tenocyte injection (ATI) is a novel cell therapy
that has shown restoration of functional tendon cells in
animal studies.4,5 Clinical and radiological improvement
was documented in a single case report employing ATI for
rotator cuff tendinopathy,26 while significant clinical and
radiological improvement was reported in a pilot study
investigating ATI for chronic lateral epicondylitis,24,25
demonstrating a sustained reduction in pain and improve-
ment in function to 4.5 years postinjection in patients
who had failed nonoperative treatment.24,25 The aim of
this pilot study was to investigate whether ATI is safe and
effective in more troublesome patients with clinical and
radiological diagnoses of gluteal tendinopathy who had
failed to respond to other nonsurgical treatments. We
hypothesized (1) that ATI is safe and well tolerated by
patients and (2) that patients will demonstrate a significant
clinical improvement sustained to 24 months postinjection.
METHODS
Participants
The first 12 patients (all female) that fit the below inclu-
sion/exclusion criteria were offered ATI as part of this pilot
trial, all recruited from a single orthopaedic surgeon’s
(G.C.J.) practice, with none refusing treatment. All
patients had symptomatic gluteal tendinopathy and had
previously undergone unsuccessful attempts at nonopera-
tive measures, including image-guided steroid injections
into the greater trochanteric bursa (n¼ 12; mean, 3.2 injec-
tions; range, 2-5), platelet-rich plasma (PRP) (n ¼ 4), and
physiotherapy (n ¼ 12). After failure of other nonoperative
measures, patients were clinically assessed by a consultant
orthopaedic surgeon and underwent magnetic resonance
imaging (MRI) to confirm the diagnosis of gluteal tendino-
pathy as well as ensure the absence of a high-grade partial-
or full-thickness gluteal tendon tear. Patients were
excluded if they had undergone previous hip and/or gluteal
repair surgery, had hip osteoarthritis, and/or received ste-
roid injections within the preceding 3 months. The mean
age of patients was 52.6 years (range, 41-67 years), with an
average duration of symptoms of 33 months (range, 6-144
months) (Table 1). Prior to treatment, all patients were
counseled regarding the procedure(s), possible risks, and
postinjection recovery before consenting to ATI and com-
pleting study documentation. Ethical approval was
obtained, and all study procedures were undertaken
according to the Declaration of Helsinki 1975.
Patella Tendon Biopsy
Under sterile conditions, the patella tendon was marked,
and a suitable area was infiltrated with local anesthetic.
Under ultrasound, a 14-gauge Tru-Cut needle was placed
in the patella tendon, and 2 biopsy specimens were taken.
Tendon tissue was placed in transport medium (DMEM F12
with 20% fetal bovine serum). As part of the Code of Good
Manufacturing Practice (GMP) for human blood and tissues
(2000) protocol, a 60-mL sample of venous blood was taken
for infection and viral screening, including: human immuno-
deficiency virus, hepatitis B and C, human T-lymphotropic
virus, and syphilis. Patients were allowed immediate full
weightbearing after the patella tendon biopsy but were
advised to limit strenuous activities for 48 hours. The same
consultant radiologist performed all procedures.
Cultivation of Autologous Tenocytes
Tenocyte cultivation was performed at Orthocell Ltd. The
tendon tissue was digested enzymatically to extract the
tenocytes. These cells were expanded by in vitro culture
in a certified Therapeutic Goods Administration (TGA)–
licensed facility. Tenocytes used for implantation were
characterized by quantitative real-time polymerase chain
reaction (PCR). It has previously been reported that this
technique maintains the tenocyte phenotype.4,5
Quantitative Real-Time PCR
Previously, we have analyzed the profile of tendon-derived
cells and identified that they contain progenitor cells that
differ from bone marrow mesenchymal stem cells and fibro-
blasts.26 To further examine whether these tendon progen-
itor cells have the capacity of producing anabolic growth
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factors that may induce matrix synthesis and cell prolifer-
ation after injection, we have examined the growth factor
profiles of these cells, including platelet-derived growth fac-
tor a (PDGFa), fibroblast growth factor b (FGFb), trans-
forming growth factor b (TGFb), bone morphogenetic
protein 2 (BMP-2), BMP-7, insulin-like growth factor 1
(IGF-1), and PDGFb. A portion of the cells from each
patient was harvested at the time of implant for cellular
characterization analysis using real-time PCR.
The total RNA was extracted from the cultured tendon-
derived cells from patients using the PureLink RNA Mini
Kit (Invitrogen; Life Technologies) according to the manu-
facturer’s instructions. The RNA from dermal fibroblast and
synovial fibroblasts was used as a control. Single-stranded
cDNA was synthesized from 1 mg of RNA using 200 U of M-
MLV reverse transcriptase, 20 U of RNasin ribonuclease
inhibitor, 0.5 mM of deoxynucleotide triphosphate, and
0.5 mg of oligo-dT 15 primer (a short sequence of deoxy-
thymine nucleotides) in a total volume of 20 mL for each
sample (Promega). To determine the gene expression profile
of the tendon-derived cells from patients, relative quantita-
tive real-time PCR was performed on a Bio-Rad MyiQ real-
time PCR system (Bio-Rad Laboratories Pty Ltd). The total
volume of each PCR reaction was 25 mL, containing 12.5 mL
SensiMix (Bioline), 0.25 mL of probe (100 nM) (Roche
Diagnostics), 6.25 mL of double-distilled water, 5 mL of
cDNA, and 0.5 mL of each primer (400 nM). These are listed
in Table 2. Real-time PCR was carried out at 95C for
15 minutes, 40 cycles at 95C for 15 seconds, 60C for
60 seconds, and 72C for 15 seconds. Housekeeping GAPDH
(glyceraldehyde 3-phosphate dehydrogenase) was included
as an internal control. A cycle threshold value was obtained
for each sample, and the comparative 2-delta-delta-CT
method was used to calculate the relative expression level
of each target gene, as previously described.
Autologous Tenocyte Injection (ATI)
In a second-stage procedure, approximately 4 weeks after
the initial tendon biopsy, patients underwent a single
tenocyte injection. The patient was placed in the lateral
decubitus position, and the skin was prepared with a suit-
able antiseptic solution. Under ultrasound, 2 mL of autolo-
gous tenocytes (2-5  106 cells/mL) suspended with 10%
autologous human serum were injected into the tendino-
pathic area using a 22-gauge needle. The same consultant
radiologist again performed all procedures. The patient was
advised to rest for 48 hours postinjection but could mobilize
as tolerated.
Clinical Assessment
All patients were independently assessed preinjection and
at 3, 6, 12, and 24 months postinjection. The primary out-
come measure was the Oxford Hip Score (OHS), and a
TABLE 1
Patient Demographics and the Oxford Hip Score (OHS) at Baseline (Preinjection) and 12 Months Postinjectiona
Patient Side Age at Treatment, y Duration of Symptoms, mo OHS (Preinjection) OHS (12 mo) OHS Change Satisfaction
1 L 62 144 19 25 6 Not sure
2 L 48 12 20 27 7 Quite dissatisfied
3 L 41 18 24 32 8 Dissatisfied
4 L 58 24 32 41 9 Quite satisfied
5 L 43 60 35 45 10 Quite satisfied
6 R 54 9 32 46 14 Highly satisfied
7 L 65 18 14 31 17 Not sure
8 L 53 11 21 38 17 Satisfied
9 L 43 48 30 48 18 Highly satisfied
10 L 65 6 28 48 20 Highly satisfied
11 R 50 24 14 37 23 Highly satisfied
12 L 49 24 19 47 28 Highly satisfied
Mean N/A 52.6 33.2 24.0 38.9 14.9 N/A
aL, left; N/A, not applicable; R, right.
TABLE 2
Growth Factor Primer Sequencesa

















aBMP, bone morphogenetic protein; FGF, fibroblast growth fac-
tor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IGF,
insulin-like growth factor; PDGF, platelet-derived growth factor;
TGF, transforming growth factor.
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minimally important clinical change for this measure has
been estimated as 11 points in patients undergoing hip
arthroplasty.1 A visual analog pain scale (VAS) was
employed to assess hip pain at rest, on a whole number
rating scale from 0 (no pain) to 10 (worst pain). Finally, the
36-item Short Form Health Survey (SF-36) was employed
to evaluate general health producing a mental component
score (MCS) and a physical component score (PCS). All
patients were asked how satisfied they were with the
results of their outcome using a 7-point satisfaction rating
scale (highly satisfied, quite satisfied, satisfied, not sure,
unsatisfied, quite dissatisfied, highly dissatisfied).
MRI Assessment
All patients underwent postinjection MRI at a mean of 8.7
months (range, 6-12 months). All scans were performed on
a Phillips Achieva 3T system (Phillips Healthcare). The
sequences utilized to evaluate the gluteal tendons were a
coronal proton density (repetition time [TR], 3500 ms; echo
time [TE], 30 ms; slice thickness, 3.5 mm), a coronal T2
fat-suppressed (TR, 4500 ms; TE, 60 ms; slice thickness,
3.5 mm), and an axial proton density fat-suppressed (TR,
3500 ms; TE, 20 ms; slice thickness, 4 mm), all obtained
with a field of view (FOV) of 18 cm.
In the absence of a recognized objective radiological scor-
ing system for gluteal tendinopathy, we adapted a scoring
tool employed by Pfirrmann et al.21 In brief, the gluteus
minimus tendon and the lateral and posterior components
of the gluteus medius tendon were analyzed separately.
Hyperintense signals extending to both surfaces of the ten-
don defined tendon tears or detachments (absent or pre-
sent), and osseous detachment of the tendon was
recorded. Tendon diameter was qualitatively rated
(normal, thinned, or thickened) based on the radiologist’s
knowledge of normal tendon anatomy. Tendon signal inten-
sity was graded as normal (hypointense) or abnormal
(increased signal intensity) compared with normal tendon
signal intensity. Abductor tendon ossification was also
documented (absent or present). Bursal fluid collections
were rated as absent or present, as was a “fan sign,”
described by Pfirrmann et al21; the fan shape made by the
muscle tissue of the gluteus medius muscle reached
the bone outline of the greater trochanter, with a positive
response documenting the presence of a defect in the
muscle tissue.
Data and Statistical Analysis
Mixed-effects regression models with random intercept and
time as a factor variable were used to estimate changes in
clinical outcomes over time. In addition to the estimate of
degree of improvement at 12 and 24 months, change from
baseline to postinjection time points for the OHS was
dichotomized as a minimal clinically important change of
11 points.1 Ninety-five percent confidence intervals and P
values are provided for all contrasts of interest. Due to the
small sample size, the nonparametric Friedman (repeated-
measures analysis of variance [ANOVA]) and Wilcoxon
signed rank test (paired t test) were also performed to
assess rank differences and confirm conclusions from
regression models. Spearman rho was used to assess
whether change in OHS at 12 months was associated with
age or duration of symptoms.
Changes in MRI measures pre- to postinjection were
assessed using the McNemar test. All pre- (n ¼ 12) and
postinjection (n ¼ 12) MRI scans were independently
reviewed and scored by 2 experienced musculoskeletal radi-
ologists, blinded to the clinical details of the cases, to eval-
uate interrater reliability. One radiologist rescored a
random sample of 20 pre-/postoperative scans to evaluate
intrarater reliability. Inter- and intrarater reliability was
assessed using the Cohen kappa and prevalence and bias-
adjusted kappa (PABAK).2 Statistical analysis was per-
formed using SPSS software (version 17.0; IBM Corp).
RESULTS
Two patients missed their 3- and 6-month clinical evalua-
tions. No patient received additional treatment during the
study period. Figure 1 shows the study flowchart.
Growth Factor Profiles of Tendon Progenitor Cells
As previously described, cultured autologous tendon-
derived cells were characterized using flow cytometry and
real-time PCR for type I collagen, scleraxis, aggrecan,
MAGP2, and Mohawk (Table 2) to ensure the purity and
potency of tendon cell phenotype. To further investigate
whether autologous tenocytes express growth factors,
real-time PCR was used to examine numbers of growth
factors that have been shown to have an anabolic effect for
tendon, cartilage, and bone. Figure 2 shows that autologous
Figure 1. Study flowchart. ATI, autologous tenocyte injection;
MRI, magnetic resonance imaging; OHS, Oxford Hip Score;
SF-36, Short Form–36; VAS, visual analog scale.
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tendon-derived cells expressed growth factors mRNA at
different levels. The majority of these cases express high
levels of mRNA for PDGFa, FGFb, and TGFb, which have
been shown to induce tendon development.10
Clinical Outcomes
Figure 3 demonstrates the incremental pattern of improve-
ment in the OHS from preinjection to 24 months. There
was statistically significant evidence for improvements
from baseline (preinjection) to 6 months postinjection
(change, 8.3 points; 95% CI, 3.9-12.8; P ¼ .009), with mean
improvement estimated to be 14.9 points by 12 months
(95% CI, 10.6-19.2; P < .001). Seven of 12 patients demon-
strated a clinically important change of 11 or more points
(Table 1). The degree of improvement in the OHS was
not estimated to be associated with age (Spearman rho,
–0.306; P ¼ .334) or the duration of symptoms (Spearman
rho, –0.182; P ¼ .572).
A pattern of incremental improvement was also observed
for the VAS and the PCS subscale of the SF-36, the majority
Figure 2. Gene expression of growth factors in autologous
tenocytes. BMP, bone morphogenetic protein; FBF, fibroblast
growth factor; GAPDH, glyceraldehyde 3-phosphate dehy-
drogenase; IGF, insulin-like growth factor; PDGF, platelet-
derived growth factor; TGF, transforming growth factor.
Figure 3. Mean (95% CI) pre- and postinjection patient-reported clinical outcomes including the (A) Oxford Hip Score, (B) visual
analog pain scale (VAS), and (C) the physical component subscale (PCS) of the 36-item Short Form Health Survey.
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of which occurred in the first 3 months (Figure 3). Evidence
of improvement from baseline to 3 months postinjection
was observed for the VAS (change, –2.8 points; 95% CI,
–4.4 to –1.2; P ¼ .001) and PCS (change, 8.8 points; 95%
CI: 3.2-14.5; P ¼ .002). An estimated mean change in the
VAS from baseline to 12 months was –4.1 (95% CI, –2.6 to
–5.6; P < .001). The mean (SD) for the PCS subscale of the
SF-36 preintervention was 28.1 (8.5) and ranged from 17.4 to
46.1. An estimated mean change in the PCS from baseline to
12 months was 15.2 (95% CI, 9.8-20.5; P < .001). The
improvement for the VAS and PCS was maintained to
24 months, with the estimated change from baseline to
24 months being –4.5 points (95% CI, –6.1 to –2.9; P < .001) for
the VAS and 12.8 points (95% CI, 7.3-18.3; P < .001) for PCS.
All 12 patients completed the patient satisfaction ques-
tionnaire at 12 months postsurgery; 5 were highly satisfied,
3 were satisfied or quite satisfied, 2 were unsure, and 2
were dissatisfied with the outcomes of their procedure.
Satisfaction at 12 months showed good concordance with
improvements at 12 months, with those patients with the
most improvement being highly satisfied and those with
the lowest being dissatisfied or unsure (see Table 1).
TABLE 3
Pre- and Postinjection MRI-Based Changes
Postinjection
Preinjection Present Absent P Valuea
Tendon defect
Gluteus minimus Present 0 0
>.999
Absent 0 12
Gluteus medius (lateral) Present 0 0
>.999
Absent 0 12




Gluteus minimus Present 0 0
>.999
Absent 0 12
Gluteus medius (lateral) Present 0 0
>.999
Absent 0 12
Gluteus medius (posterior) Present 0 0
>.999
Absent 0 12
Bursal fluid collection and fan sign
Bursal fluid collection Present 3 4
.125
Absent 0 5





Gluteus minimus Normal 1 0
>.999
Abnormal 1 10
Gluteus medius (lateral) Normal 3 0
>.999
Abnormal 1 8





Gluteus minimus Thinning 3 0 0
>.999bNormal 0 0 0
Thickening 1 1 7
Gluteus medius (lateral) Thinning 3 0 0
>.999bNormal 0 5 0
Thickening 0 0 4
Gluteus medius (posterior) Thinning 0 0 0
>.999bNormal 0 10 1
Thickening 0 0 1
aMcNemar exact test.
bTo perform McNemar test, data collapsed to thinning yes/no.
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MRI Outcomes
We sought to examine whether the pathological features of
tendinopathy seen on MRI were correlated with the clinical
outcome after ATI. We observed no significant improve-
ment from pre- to postinjection in any tendon features mea-
sured by MRI (Table 3). Intrarater agreement was absolute
or high for all MRI measures (PABAK range from 0.727 to
1.00). Interrater agreement was absolute or high for all
MRI measures, with the exception of tendon signal inten-
sity for the lateral portion of the gluteus medius (Table 4).
Figure 4 shows the pre- and postinjection MRI for 1 patient,
demonstrating improved appearances.
Complications
There were no injection or biopsy site infections, though 3
patients reported some immediate discomfort at the patella
tendon biopsy site, all of which responded to topical nonste-
roidal anti-inflammatory gel. There have been no long-term
complications related to the biopsy site. There were no com-
plications after the ATI injection. One patient (patient 1,
Table 1) did not respond to ATI treatment and has since
undergone surgery to repair her gluteal tendon, after her
12-month review. This patient reported a change in the
OHS from 19 to 25 (pre- to 12 months postinjection), though
also reported a prior duration of symptoms of 12 years.
TABLE 4




Kappa PABAKaRadiologist 1 Present Absent
Tendon Defect
Gluteus Minimus Present 0 0
1.000 1.000
Absent 0 24
Gluteus Medius (Lateral) Present 0 0
1.000 1.000
Absent 0 24




Gluteus Minimus Present 0 0
1.000 1.000
Absent 0 24
Gluteus Medius (Lateral) Present 0 0
1.000 1.000
Absent 0 24
Gluteus Medius (Posterior) Present 0 0
1.000 1.000
Absent 0 24
Bursal Fluid Collection & Fan Sign
Bursal Fluid Collection Present 7 3
0.731 0.752
Absent 0 14





Gluteus Minimus Normal 3 0
0.704 0.830
Abnormal 2 19
Gluteus Medius (Lateral) Normal 5 2
0.442 0.500
Abnormal 4 13





Gluteus Minimus Thinning 7 0 0
0.586 0.625Normal 0 1 0
Thickening 2 4 10
Gluteus Medius (Lateral) Thinning 6 0 0
0.936 0.938Normal 0 10 0
Thickening 0 1 7
Gluteus Medius (Posterior) Thinning 0 0 0
0.000 0.812Normal 0 21 0
Thickening 0 3 0
aPrevalence and bias adjusted kappa.
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DISCUSSION
Gluteus medius and/or minimus tendinopathy is now
accepted as the most prevalent pathology in those with pain
and tenderness over the greater trochanter,11 though
conservative treatment modalities demonstrate high
symptom recurrence rates.18,19 In an attempt to explore
advanced therapeutic options, we have conducted the first
prospective case study of ATI specifically in patients with
chronic gluteal tendinopathy. In this study, we have dem-
onstrated that ATI significantly improved early clinical
patient-reported outcomes, with further improvement and
sustained benefit to 24 months. All patients in this study
reported improvement in the OHS, with 7 of 12 patients
demonstrating a clinically important change of 11 or more
points by 12 months. A similar pattern of incremental
improvement was observed for the VAS and the PCS sub-
scale of the SF-36.
Currently, steroid injections are the mainstay of treatment
for gluteal tendinopathy,22 and while they have demon-
strated good short-term efficacy,15 recurrence of pain is com-
mon.8 This was reflected in this study, with patients
undergoing an average of 3.2 prior injections (range, 2-5),
with no benefit from their most recent injection. It has been
shown that apoptosis and autophagic cell death are common
in other tendinopathic conditions.3 This, coupled with the
lack of inflammation seen with tendinopathic conditions,
may explain why steroid injections do not give long-lasting
relief of symptoms and provides rationale for investigating
the potential benefit of ATI. In comparison with a study by
Labrosse et al,15 who showed only short-term benefits after
steroid injections, patients in this pilot trial displayed
early improvement in pain scores that were sustained up
to 24 months after ATI. Our data demonstrate promise in
the use of ATI in the treatment of gluteal tendinopathy.
Recently, other injection therapies such as PRP or auto-
logous blood have become increasingly popular for their
potential application in the treatment of tendinopathy.
Although the product of ATI contains 10% patient serum
without platelets and white blood cells, it is very unlikely
that 10% autologous human serum will have any effect on
the clinical outcome. This is supported by a recent meta-
analysis on the effect of PRP in tendinopathy, which dem-
onstrated that only leukocyte-rich PRP has a therapeutic
effect on tendinopathy.9 According to manufacture require-
ments, the presence of 10% patient serum within ATI is
used for cell stability as it contains a high concentration
of human albumin. The fact that 4 of these patients had
previously received intratendon PRP injections without
benefit also reiterates the minimum therapeutic impact of
10% serum in the injection media.
Animal studies have demonstrated that autologous teno-
cytes are effective in treating chronic tendon degenera-
tion.4,5 Others have injected tenocyte-like cells cultured
from skin fibroblasts into tendinopathic tendons.6,7 The
presented ATI technique differs from previously published
methods in that tenocytes are prepared from the same cell
line rather than collagen-producing tenocyte cells used
from skin fibroblasts. ATI has already demonstrated
improved clinical (and radiological) outcomes in patients
with chronic lateral epicondylitis.24,25 A similar benefit has
also been shown for ATI in the rotator cuff.26 Given the
apoptosis and autophagic cell death seen in chronic tendi-
nopathy,3 one of the potential mechanisms of action of ATI
contributing to the clinical improvement observed may be
the incorporation of Feridex-labeled injected tenocytes into
the tendon matrix, seen previously in an animal study.4 In
addition, this study also showed that injected autologous
tenocytes may produce growth factors, including FGFb,
TGFb, and PDGFa, that can act in the autocrine and para-
crine actions for the induction of tendon cell proliferation
and matrix production.
Despite the statistically significant improvement in clinical
scores, we failed to demonstrate obvious MRI-based
Figure 4. Coronal magnetic resonance image of the same patient (A) preinjection and (B) at 6 months after autologous tenocyte
injection demonstrating a reduction in both gluteus medius tendon thickness (arrow) and the extent of intratendon T2 high signal
intensity.
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improvement in the majority of cases. A recent review by
McMahon et al20 suggested that while a paucity of data exist
for the management and imaging of these conditions, MRI
should be the imaging modality of choice in the investigation
of GTPS. However, studies tend to concentrate on the effec-
tiveness of MRI for predicting the presence of a tear rather
than tendinopathy. Furthermore, while MRI has demon-
strated benefit in the pretreatment diagnosis and planning
for a patient with clinical signs of GTPS, to our knowledge,
there are no studies evaluating the appearance of gluteal
tendons after treatments such as injections, nor is there a
preexisting validated tool to evaluate improvement from an
intervention. MRI performed after surgical repair of glu-
teal tendons often demonstrates ongoing tendon abnormal-
ity and thickening,16 while a recent systematic review
found that false positives were common when assessing the
accuracy of MRI for gluteal tendon tears.27 Westacott
et al27 concluded that better designed studies demonstrate
poor accuracy and that ultrasound in skilled hands may be
the investigation of choice. This becomes relevant when
considering our inability to demonstrate obvious radiolog-
ical improvement in the majority of cases, despite the
reported clinical improvement.
Our study does have several limitations. Firstly, small
case numbers were investigated given the primary out-
come was safety specifically in the use of ATI for gluteal
tendinopathy. While a safety study has been previously
undertaken for lateral epicondylitis,24,25 the gluteal ten-
don is a different and weightbearing tendon and may
behave in a different way to the upper limb. Second, we
acknowledge the lack of a comparative group and the
potential for clinical changes that could occur purely as a
result of placebo or the natural recovery time line (partic-
ularly in those with a shorter duration of symptoms). How-
ever, it should also be noted that statistically significant
evidence for improvements was noted by 6 months postin-
jection, and the shortest symptom duration reported was 6
months. Furthermore, all 12 patients had failed to obtain
benefit from other conservative treatments such as struc-
tured exercise, had received no benefit (or were worse)
from their most recent cortisone injections (with patients
undergoing an average of 3.2 prior injections), and had a
duration of symptoms of on average 33.2 months (mini-
mum, 6 months; 9 patients at least 12 months; 6 patients
at least 24 months). Furthermore, the improvements
obtained were sustained for 24 months, which, combined
with the history of failed prior treatment in these patients,
may well show benefit beyond a placebo response in the
absence of a control group. Third, we employed the OHS, a
clinical measure specific for hip osteoarthritis, as our pri-
mary outcome clinical tool. While it would appear that the
OHS has good face validity for GTPS, there is currently no
validated patient-reported outcome measure for gluteal
tendinopathy or GTPS. Finally, we sought to investigate
MRI-based changes in addition to clinical improvement.
We acknowledge that obvious radiological improvement
in the majority of cases could not be demonstrated despite
the reported clinical improvement. This may be limited by
our lack of a preexisting validated tool to evaluate MRI
improvement from an intervention or that postinjection
MRI was undertaken too early, given that 1- and 4.5-
year MRI improvement has been reported using ATI for
lateral epicondylitis.24,25 These are areas for future
research.
CONCLUSION
This study demonstrated safety in using ATI specifically in
the treatment of recalcitrant gluteal tendinopathy. There
were no persistent complications as a result of the tendon
biopsy or tenocyte injection. Furthermore, this prospective
case series revealed significant and sustained improvement
in clinical scores to 24 months after ATI in patients who had
previously undergone unsuccessful conservative treat-
ments. Given that gluteal tendinopathy remains a chal-
lenging condition to treat, especially when conventional
conservative measures fail, this pilot study has provided
useful data and shown sufficient promise for the design of
a randomized controlled study investigating ATI for gluteal
tendinopathy.
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